ImmunityBio gets FDA review for Anktiva label expansion (IBRX)

ImmunityBio (IBRX) rose about 9% in premarket trading after the FDA accepted its marketing application to expand the label of bladder cancer therapy Anktiva. The filing acceptance is a positive regulatory step that could broaden the drug’s commercial opportunity in the U.S. and support investor sentiment toward the company.

Analysis

ImmunityBio (IBRX) rose about 9% in premarket trading after the FDA accepted its marketing application to expand the label of bladder cancer therapy Anktiva. The filing acceptance is a positive regulatory step that could broaden the drug’s commercial opportunity in the U.S. and support investor sentiment toward the company.